Pegylated interferon for hepatitis C receives "complete response" letter from FDA April 10. Outstanding issues are not related to safety or efficacy, Roche says
You may also be interested in...
Roche's "current expectation" for the pegylated interferon product Pegasys is that it will be approved in the first half of 2002, with an indication covering both monotherapy and combination use.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011